Colorectal Cancer Clinical Trials in Philadelphia, PA

Colorectal Cancer Clinical Trials in Philadelphia, PA

View the best 10 colorectal cancer medical studies in Philadelphia, Pennsylvania. Access promising new therapies by applying to a Philadelphia-based Colorectal Cancer clinical trial.

Top rated colorectal cancer clinical trials in Philadelphia, Pennsylvania

Here are the top 10 medical studies for colorectal cancer in Philadelphia, Pennsylvania

Image of Fox Chase Cancer Center in Philadelphia, United States.

Linaclotide

Guanylate Cyclase-C Agonist

Recruiting0 awardsPhase 2
This trial is testing how well linaclotide works in treating patients with early stage colorectal cancer. Linaclotide is a protein that makes intestinal cells secrete water and salt.
Image of CTCA at Western Regional Medical Center in Goodyear, United States.

Trastuzumab +3 More

Monoclonal Antibodies

Recruiting1 awardPhase 2
This trial studies trastuzumab and pertuzumab compared to cetuximab and irinotecan hydrochloride in treating patients with HER2/neu amplified colorectal cancer.
Image of Exelixis Clinical Site #53 in Gilbert, United States.

Cabozantinib +1 More

Tyrosine Kinase Inhibitor

Recruiting1 awardPhase 1 & 2
This trial is testing the safety and effectiveness of a new cancer drug when used in combination with another cancer drug. The new drug is being tested on people with different types of cancer, including bladder, kidney, prostate, and breast cancer.
Image of Kimmel Cancer Center at Thomas Jefferson University - Philadelphia in Philadelphia, United States.

Personalized Invitations

Behavioural Intervention

Recruiting2 awardsPhase 3
This trial is studying whether sending personalized invitations to African Americans for colorectal cancer screening is more effective than standard reminders.
Image of Stanford Cancer Center / Blood and Marrow Transplant Program in San Jose, United States.

Tisotumab Vedotin

Antibody-Drug Conjugate

Recruiting1 awardPhase 2
This trial will study tisotumab vedotin to find out whether it is an effective treatment for certain solid tumors and what side effects (unwanted effects) may occur. There are four parts to this study.
Image of HonorHealth Research Institute in Scottsdale, United States.

INBRX-109

Monoclonal Antibodies

Recruiting1 awardPhase 1
This trial is testing a new drug, INBRX-109, which is a recombinant humanized tetravalent antibody targeting the human death receptor 5 (DR5). This is the first time this drug is being tested in humans. The trial has three parts.
Image of Kaiser Permanente in Los Angeles, United States.

Transanal Total Mesorectal Excision (taTME)

Procedure

Recruiting1 award10 criteria
This trial is a phase II multicenter single-arm study to evaluate the safety and efficacy of low anterior resection (LAR) with taTME using laparoscopic or robotic assistance in 100 eligible subjects with resectable rectal cancer.
Image of City of Hope (City of Hope National Medical Center, City of Hope Medical Center) in Duarte, United States.

Encorafenib +1 More

Kinase Inhibitor

Recruiting2 awardsPhase 3
This trial is testing a new combination of drugs to treat colorectal cancer that has spread and has a certain type of abnormal gene. The new combination is encorafenib plus cetuximab, which will be taken either alone or with standard chemotherapy.
Image of NRG Oncology - Pittsburgh Center in Pittsburgh, United States.

Capecitabine +4 More

Chemotherapy

Recruiting1 awardPhase 2 & 3
This trial tests how well ctDNA testing in the blood predicts treatment for patients with stage IIA colon cancer after surgery. ctDNA are circulating tumor cells that are shed by tumors into the blood. Finding ctDNA in the blood means that there is very likely some small amounts of cancer that remain after surgery. However, this cancer, if detected, cannot be found on other tests usually used to find cancer, as it is too small. Testing for ctDNA levels may help identify patients with colon cancer after surgery who do benefit, and those who do not benefit, from receiving chemotherapy.
Image of UCSF Helen Diller Family Comprehensive Cancer Center in San Francisco, United States.

9-ING-41

GSK-3β inhibitor

Recruiting1 awardPhase 2
This trial is testing a new drug to see if it is safe and effective in treating cancer. The drug is designed to target a protein called GSK-3β, which is found in many different types of cancer cells.

Popular filter options for colorectal-cancer philadelphia trials

Phase 3 Clinical Trials

View 97 phase 3 medical studies.

Clinical Trials With No Placebo

View 97 medical studies that do not have a placebo group.

Frequently Asked Questions

Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the 'trial drug' — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
Is there any support for travel costs?
Many of the teams running clinical trials will cover the cost of transportation to-and-from their care center.
Will I know what medication I am taking?
This depends on the specific study. If you're worried about receiving a placebo, you can actively filter out these trials using our search.
How long do clinical trials last?
Some trials will only require a single visit, while others will continue until your disease returns. It's fairly common for a trial to last somewhere between 1 and 6 months.
Do you verify all the trials on your website?
All of the trials listed on Power have been formally registered with the US Food and Drug Administration. Beyond this, some trials on Power have been formally 'verified' if the team behind the trial has completed an additional level of verification with our team.
How quickly will I hear back from a clinical trial?
Sadly, this response time can take anywhere from 6 hours to 2 weeks. We're working hard to speed up how quickly you hear back — in general, verified trials respond to patients within a few days.